Last reviewed · How we verify
Standard dose: standard XELOX + sintilimab
Standard dose: standard XELOX + sintilimab is a Chemotherapy + PD-1 inhibitor combination Small molecule drug developed by Sun Yat-sen University. It is currently in Phase 3 development for Gastric or gastroesophageal junction cancer (Phase 3 trial setting).
XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotoxicity while simultaneously unleashing immune cells to attack tumors by blocking the PD-1 checkpoint.
XELOX chemotherapy combined with sintilimab (a PD-1 inhibitor) works by killing cancer cells through chemotoxicity while simultaneously unleashing immune cells to attack tumors by blocking the PD-1 checkpoint. Used for Gastric or gastroesophageal junction cancer (Phase 3 trial setting).
At a glance
| Generic name | Standard dose: standard XELOX + sintilimab |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Chemotherapy + PD-1 inhibitor combination |
| Target | PD-1 (sintilimab component); DNA/thymidylate synthase (XELOX component) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
XELOX is a combination of capecitabine and oxaliplatin that damages cancer cell DNA and prevents replication. Sintilimab is a humanized monoclonal antibody that blocks PD-1 on T cells, preventing tumor cells from suppressing the immune response. Together, they provide both direct cytotoxic effects and immune checkpoint relief to enhance anti-tumor immunity.
Approved indications
- Gastric or gastroesophageal junction cancer (Phase 3 trial setting)
Common side effects
- Neutropenia
- Diarrhea
- Nausea/vomiting
- Hand-foot skin reaction
- Immune-related adverse events (fatigue, hepatotoxicity)
Key clinical trials
- Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by Surgery-centric Local Treatment in Patients With Limited-metastatic Gastric Cancer (PHASE2)
- Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer (PHASE2)
- Intestinal Microbiota Transplantation, Radiochemotherapy and Sintilimab in Localized Advanced Colon Cancer (PHASE4)
- Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma (PHASE3)
- Radiotherapy + Chemoimmunotherapy Followed by Surgery in Patients With Limited Metastatic Gastric or GEJ Cancer (PHASE2)
- PD-1 Antibody Adjuvant Therapy for GC Patients With MSI-H After D2 Radical Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Standard dose: standard XELOX + sintilimab CI brief — competitive landscape report
- Standard dose: standard XELOX + sintilimab updates RSS · CI watch RSS
- Sun Yat-sen University portfolio CI
Frequently asked questions about Standard dose: standard XELOX + sintilimab
What is Standard dose: standard XELOX + sintilimab?
How does Standard dose: standard XELOX + sintilimab work?
What is Standard dose: standard XELOX + sintilimab used for?
Who makes Standard dose: standard XELOX + sintilimab?
What drug class is Standard dose: standard XELOX + sintilimab in?
What development phase is Standard dose: standard XELOX + sintilimab in?
What are the side effects of Standard dose: standard XELOX + sintilimab?
What does Standard dose: standard XELOX + sintilimab target?
Related
- Drug class: All Chemotherapy + PD-1 inhibitor combination drugs
- Target: All drugs targeting PD-1 (sintilimab component); DNA/thymidylate synthase (XELOX component)
- Manufacturer: Sun Yat-sen University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Gastric or gastroesophageal junction cancer (Phase 3 trial setting)
- Compare: Standard dose: standard XELOX + sintilimab vs similar drugs
- Pricing: Standard dose: standard XELOX + sintilimab cost, discount & access